Wellington Management Group LLP Sells 47,776 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Wellington Management Group LLP has reduced its stake in Teva Pharmaceutical Industries by 25.7%, selling 47,776 shares and retaining 138,136 shares valued at approximately $2.12 million.
• Several institutional investors have recently increased their holdings in Teva, with Northern Trust Corp raising its stake by 69%, owning over 5.2 million shares worth around $114.75 million.
• Teva's stock received multiple buy ratings from analysts, with a target price range between $22.00 and $25.00, reflecting positive growth expectations for the company.

Wellington Management Group LLP cut its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 25.7% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 138,136 shares of the company's stock after selling 47,776 shares during the quarter. Wellington Management Group LLP's holdings in Teva Pharmaceutical Industries were worth $2,123,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Harel Insurance Investments & Financial Services Ltd. boosted its position in Teva Pharmaceutical Industries by 197,885.2% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company's stock worth $338,989,000 after acquiring an additional 22,044,407 shares during the last quarter. Duquesne Family Office LLC boosted its position in Teva Pharmaceutical Industries by 530.1% during the 4th quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company's stock worth $198,303,000 after acquiring an additional 7,569,450 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its position in Teva Pharmaceutical Industries by 472.8% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 6,283,688 shares of the company's stock worth $96,078,000 after acquiring an additional 5,186,592 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in Teva Pharmaceutical Industries by 416.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 5,983,928 shares of the company's stock worth $91,973,000 after acquiring an additional 4,824,247 shares during the last quarter. Finally, Nuveen LLC acquired a new position in Teva Pharmaceutical Industries during the 1st quarter worth approximately $40,827,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock traded down $0.16 during mid-day trading on Thursday, hitting $18.60. 3,051,659 shares of the company's stock traded hands, compared to its average volume of 12,020,283. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. The stock has a market cap of $21.33 billion, a price-to-earnings ratio of -115.79, a P/E/G ratio of 1.09 and a beta of 0.72. The firm has a 50 day simple moving average of $16.95 and a two-hundred day simple moving average of $16.37. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.02. The firm had revenue of $4.18 billion for the quarter, compared to analysts' expectations of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The company's quarterly revenue was up .3% compared to the same quarter last year. During the same quarter last year, the business earned $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Placid Jover sold 6,053 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the transaction, the insider owned 6,774 shares in the company, valued at $102,693.84. This trade represents a 47.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eric A. Hughes sold 52,742 shares of the firm's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $799,568.72. The disclosure for this sale can be found here. 0.55% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Truist Financial assumed coverage on Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They set a "buy" rating and a $25.00 price target for the company. UBS Group cut their price objective on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a report on Thursday, June 26th. The Goldman Sachs Group initiated coverage on Teva Pharmaceutical Industries in a report on Friday, June 6th. They issued a "buy" rating and a $24.00 price objective for the company. Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Finally, JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and increased their price objective for the company from $21.00 to $23.00 in a report on Monday, May 12th. Two equities research analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $24.71.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.